Alkermes PE Ratio 2006-2021 | ALKS

Current and historical p/e ratio for Alkermes (ALKS) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Alkermes PE ratio as of October 22, 2021 is 146.90.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Alkermes PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 30.85 0.00
2021-06-30 24.52 $-0.40 0.00
2021-03-31 18.68 $-0.60 0.00
2020-12-31 19.95 $-0.70 0.00
2020-09-30 16.57 $-0.46 0.00
2020-06-30 19.41 $-0.80 0.00
2020-03-31 14.42 $-0.88 0.00
2019-12-31 20.40 $-1.26 0.00
2019-09-30 19.51 $-1.29 0.00
2019-06-30 22.54 $-1.17 0.00
2019-03-31 36.49 $-1.11 0.00
2018-12-31 29.51 $-0.89 0.00
2018-09-30 42.44 $-0.89 0.00
2018-06-30 41.16 $-0.91 0.00
2018-03-31 57.96 $-0.98 0.00
2017-12-31 54.73 $-1.03 0.00
2017-09-30 50.84 $-1.11 0.00
2017-06-30 57.97 $-1.28 0.00
2017-03-31 58.50 $-1.31 0.00
2016-12-31 55.58 $-1.37 0.00
2016-09-30 47.03 $-1.69 0.00
2016-06-30 43.22 $-1.82 0.00
2016-03-31 34.19 $-1.82 0.00
2015-12-31 79.38 $-1.52 0.00
2015-09-30 58.67 $-0.86 0.00
2015-06-30 64.34 $-0.59 0.00
2015-03-31 60.97 $-0.26 0.00
2014-12-31 58.56 $-0.22 0.00
2014-09-30 42.87 $-0.30 0.00
2014-06-30 50.33 $-0.09 0.00
2014-03-31 44.09 $-0.06 0.00
2013-12-31 40.66 $0.13 312.77
2013-09-30 33.62 $0.13 258.62
2013-06-30 28.68 $0.06 478.00
2013-03-31 23.70 $0.18 131.67
2012-12-31 18.52 $-0.33 0.00
2012-09-30 20.75 $-0.56 0.00
2012-06-30 16.97 $-0.65 0.00
2012-03-31 18.55 $-0.96 0.00
2011-12-31 17.36 $-0.47 0.00
2011-09-30 15.25 $-0.48 0.00
2011-06-30 18.60 $-0.34 0.00
2011-03-31 12.95 $-0.34 0.00
2010-12-31 12.28 $-0.34 0.00
2010-09-30 14.65 $-0.29 0.00
2010-06-30 12.45 $-0.30 0.00
2010-03-31 12.97 $-0.27 0.00
2009-12-31 9.41 $-0.27 0.00
2009-09-30 9.19 $0.98 9.38
2009-06-30 10.82 $1.09 9.93
2009-03-31 12.13 $1.51 8.03
2008-12-31 10.65 $1.51 7.05
2008-09-30 13.30 $1.96 6.79
2008-06-30 12.36 $2.01 6.15
2008-03-31 11.88 $1.78 6.67
2007-12-31 15.59 $1.78 8.76
2007-09-30 18.40 $0.18 102.22
2007-06-30 14.60 $0.15 97.33
2007-03-31 15.44 $0.06 257.33
2006-12-31 13.37 $0.06 222.83
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.977B $1.039B
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76